FDA reviewers back approval of Merck's blood-clot drug

01/13/2014 | Reuters · Medscape (free registration)

Ahead of an FDA advisory panel meeting Wednesday, FDA reviewers recommended the approval of Merck & Co.'s experimental blood-clot drug Zontivity, or vorapaxar, for prevention of stroke, cardiac arrest and cardiac-related death in patients who recently had a heart attack. The recommendation was based on "robustly positive" data from the TRA 2P trial.

View Full Article in:

Reuters · Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Santa Ana, CA